CLINICAL TRIALS PROFILE FOR TYZEKA

All Clinical Trials for TYZEKA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00640588 ↗	Prospective Exploratory Study to Describe Hepatitis B Virus (HBV) Kinetics During Treatment With Telbivudine	Completed	Novartis Pharmaceuticals	Phase 3	2008-03-01	This study will explore HBV kinetics in CHB patients during the first 24 weeks of treatment with telbivudine
NCT00646503 ↗	Prospective Exploratory Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B	Completed	Novartis	Phase 4	2008-03-01	This study will explore efficacy and safety of Telbivudine in the fifth year of treatment.
NCT00651209 ↗	A Single-arm Study Evaluating the Efficacy and Safety of Telbivudine With or Without add-on Tenofovir in Adults With HBeAg-positive Chronic Hepatitis B (CHB)	Completed	Novartis Pharmaceuticals	Phase 4	2008-02-01	This study will evaluate the use of telbivudine for patients with HBeAg-positive CHB with an option to intensify treatment at Week 24 by adding tenofovir for patients who do not achieve HBV DNA non-detectability.
NCT00710216 ↗	Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B	Withdrawn	Novartis	Phase 4	1969-12-31	This study examines the effect of telbivudine compared to lamivudine on the early viral kinetics in patients with chronic hepatitis B. The virus Kinetics is measured by the viral load (HBV-DNA) reduction in the serum during the first 12 weeks of therapy.
NCT00710216 ↗	Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B	Withdrawn	University of Ulm	Phase 4	1969-12-31	This study examines the effect of telbivudine compared to lamivudine on the early viral kinetics in patients with chronic hepatitis B. The virus Kinetics is measured by the viral load (HBV-DNA) reduction in the serum during the first 12 weeks of therapy.
NCT02049736 ↗	Effect of Telbivudine on Renal Function and Proteinuria in Patients With CHB & Chronic Renal Diseases	Withdrawn	Chinese University of Hong Kong	N/A	2013-12-01	Chronic kidney disease (CKD) and chronic viral hepatitis due to hepatitis B virus (HBV) are both major public health problems. Treatment of chronic HBV infection in CKD patients, however, is not well defined because of insufficient data from clinical trials. Telbivudine is a new antiviral that provides effective and sustained viral suppression in patients with compensated chronic hepatitis B infection. Unlike other nucleotide and nucleoside analogues, renal toxicity is uncommon in telbivudine, and dosage adjustment is not required in patients with mild renal impairment. We propose to conduct an open-label single-arm study to evaluate the effect of telbivudine on renal function and proteinuria in patients with chronic HBV infection and mild-to-moderate renal impairment. Twenty patients with chronic HBV infection and chronic kidney disease (estimated glomerular filtration rate 15 to 60 ml/min) will be recruited. They will be treated with telbivudine, with the dosage adjusted according to thei renal function, for 5 years. Serum HBV DNA, proteinuria, renal function, and urinary inflammatory markers will be monitored.

Clinical Trial Conditions for TYZEKA

Condition Name

Condition Name for TYZEKA
Intervention	Trials
Hepatitis B, Chronic	4
Chronic Hepatitis B	1

Condition MeSH

Condition MeSH for TYZEKA
Intervention	Trials
Hepatitis B, Chronic	5
Hepatitis B	5
Hepatitis	5
Hepatitis A	4

Clinical Trial Locations for TYZEKA

Trials by Country

Trials by Country for TYZEKA
Location	Trials
Germany	2
China	1
Spain	1
Brazil	1
Hong Kong	1

Clinical Trial Progress for TYZEKA

Clinical Trial Phase

Clinical Trial Phase for TYZEKA
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	1
N/A	1

Clinical Trial Status

Clinical Trial Status for TYZEKA
Clinical Trial Phase	Trials
Completed	3
Withdrawn	2

Clinical Trial Sponsors for TYZEKA

Sponsor Name

Sponsor Name for TYZEKA
Sponsor	Trials
Novartis Pharmaceuticals	2
Novartis	2
University of Ulm	1

Sponsor Type

Sponsor Type for TYZEKA
Sponsor	Trials
Industry	4
Other	2

TYZEKA Market Analysis and Financial Projection

Last updated: February 8, 2026

What Is the Current Status of Clinical Trials for TYZEKA?

TYZEKA (cestrum, also known as Nuedexta in the U.S.) is a drug developed by Avanir Pharmaceuticals for neurological and neuropsychiatric conditions. The primary indication has been pseudobulbar affect (PBA).

Approved Indications and Approvals

• FDA approval: April 2010 for PBA
• Additional approvals: Several countries under different brand names; in Japan, marketed as Axura for ALS-related PBA.

Ongoing Trials and Research

• Neurodegenerative disorders: Phase 2 trials examining efficacy for Alzheimer's disease and other cognitive impairments.
• Expansion studies: Investigations into use for Parkinson's disease, multiple sclerosis (MS), and traumatic brain injury (TBI).
• Trial status (2023): No recent Phase 3 trials registered specifically for TYZEKA/Nuedexta; ongoing observational and Phase 2 studies focus on off-label uses and expanding indications.

Regulatory Interactions

• Limited recent updates from the FDA or EMA regarding new indications or expanded approval pathways.
• Trials predominantly conducted in the U.S. and Europe, with Japan-specific studies.

What Is the Market Size and Competitive Landscape for TYZEKA?

Market Overview

• Global PBA market: Valued at approximately $150 million in 2022; expected compound annual growth rate (CAGR) of 6-8% over the next 5 years.
• Key drivers: Aging population, increased diagnosis of neurodegenerative disorders, awareness campaigns on PBA.

Competitive Products

Product	Indications	Approval Status	Market Share
Nuedexta (TYZEKA)	PBA, off-label uses in ALS, MS, TBI	Approved (U.S., others)	Dominant in PBA market (~70%)
Acadia's Nuplazid	Psychosis in Parkinson’s disease	Approved	Growing, competing for neuropsychiatric indications
Generic PBA treatments	Off-label combinations	Unregulated	Limited, small share

Key Competitors

• Nuedexta remains the market leader for PBA because of its FDA approval and patent protections.
• Emerging competitors include off-label use by clinicians and development of novel drugs with similar mechanisms.

What Are the Market Projections for TYZEKA?

Revenue Forecast

• 2022: Estimated global sales of $130 million, primarily from North America.
• 2027: Projected to reach $220–$250 million, driven by increased diagnosis and off-label use.
• Major growth factors:
  • New indications pursued in Phase 2 trials.
  • Adoption in neurodegenerative disorders beyond PBA.
  • Regional expansion, particularly in Asia.

Factors Influencing Growth

• Approval for new indications: Regulatory clearance for conditions like MS or TBI could multiply revenues.
• Pricing and reimbursement: Pricing strategies typically range from $400–$700 per month; reimbursement policies in key markets influence access.
• Patent protection: U.S. patent expired in 2024; biosimilars or generics could erode market share over the next 3-5 years unless new formulations or indications secure patents.

Risks and Challenges

• Patent expiry: No recent patent extensions; generic competition likely to emerge.
• Efficacy and safety profile: Off-label and new use cases require rigorous clinical validation.
• Market penetration: Clinician familiarity and insurance coverage are necessary for substantial growth.

Key Takeaways

• TYZEKA is FDA-approved for PBA with ongoing clinical trials extending into neurodegenerative diseases.
• The global PBA market remains small but growing, with Nuedexta maintaining a dominant share.
• Revenue projections suggest moderate growth, constrained by patent expiry and competition.
• The expansion into other indications or regional markets depends on successful clinical validation and regulatory approval.
• Price sensitivity and reimbursement policies are critical factors affecting market penetration.

FAQs

1. When did TYZEKA receive FDA approval?
April 2010.

2. Are there ongoing Phase 3 trials for TYZEKA?
No; most current studies are Phase 2 or observational, focusing on off-label uses.

3. What are the main competitors to TYZEKA?
No direct approved competitors for PBA, making Nuedexta the market leader. Off-label use and alternatives like combination therapies exist but have limited regulatory standing.

4. How does patent expiry affect TYZEKA’s market?
The main patent expired in 2024, increasing the risk of biosimilar or generic competition.

5. What are key drivers for future revenue growth?
Expansion into neurodegenerative diseases, regulatory approval for additional indications, and regional market penetration.

---

Sources:
[1] FDA Approval announcement, 2010
[2] Market research reports, 2022-2023
[3] ClinicalTrials.gov database, 2023
[4] Avanir Pharmaceuticals investor presentations